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Abstract
Background: Pulmonary administration of colistin is one of the antimicrobial treatments used in Cystic Fibrosis (CF) patients
chronically infected with Pseudomonas aeruginosa. Dry powder inhalation of colistin may be an attractive alternative to
nebulization of colistin. However, nebulized colistin can cause bronchoconstriction in CF patients. Therefore, in the progress of
developing a dry powder formula, the choice of the inhaler and its contents should be guided by optimal efficacy and the least
possible side effects. To investigate the side effects, a study was initiated to compare the tolerability of colistin sulphate to colistin
sulphomethate per nebulization in CF-patients. Methods: Nine CF-patients chronically infected with P. aeruginosa participated in
a double blind, randomized cross over study. On two visits to the outpatient clinic, patients were submitted to either nebulized
colistin sulphate or colistin sulphomethate solution. Lung function tests were performed immediately before and 15 and 30 min
after nebulization. Results: Nebulization of colistin sulphate caused a significant larger mean decrease in lung function compared
to nebulized colistin sulphomethate. A significant decrease in mean changes (SD) in FEV1 at 30 min and FVC at 15 and 30 min
after nebulization compared to baseline of y7.3% (8.6%), y5.7% (7.3%) and y8.4% (7.5%) respectively was seen after colistin
sulphate nebulization compared to colistin sulphomethate (P-0.05). Seven patients were not able to complete the nebulization
of colistin sulphate because of throat irritation and severe cough. Conclusion: Based on these results it was concluded that
inhalation with nebulized colistin sulphate is not suitable for treatment of CF patients chronically infected with P. aeruginosa.
Colistin sulphomethate is the drug of choice for pulmonary administration of colistin.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Nebulized colistin is one of the antimicrobial agents
recommended for use in patients with Cystic fibrosis
(CF) chronically infected with Pseudomonas aeruginosa
w1x. For this therapy, commercially available vials for
intravenous administration, containing colistin as sul-
phomethate, are generally used. As nebulization of drugs
in general is a time consuming activity, influencing daily
life of patients, an alternative method of pulmonary
delivery of colistin would be welcome. Therefore, dry
powder inhalation of colistin may be an attractive
alternative to nebulization of colistin in CF-patients w3x.
*Corresponding author.
E-mail address: e.westerman@ahz.nl (E.M. Westerman).
In vivo, colistin sulphomethate is transformed into
colistin sulphate, which is thought to have a more potent
antibacterial effect than the parent compound w2x. There-
fore, we initially considered colistin sulphate as the
compound of choice in the development of a colistin
dry powder for inhalation.
In a previous pilot study, the feasibility of colistin
sulphate as a dry powder inhalation was investigated
both in healthy volunteers and in patients w3x. This
newly developed dry powder inhalation system was
highly appreciated by the patients and provided a pul-
monary deposition comparable to the deposition
observed after nebulization of colistin sulphomethate
solution. However, as reported, a decrease in pulmonary
function and the occurrence of non productive cough
after dry powder inhalation of colistin sulphate was
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Fig. 1. Questionnaire.
observed in a number of patients, whereas no such
effects were seen in the volunteer group. Furthermore,
no such side effects were observed in CF-patients after
nebulization of colistin as sulphomethate. The origin of
the side effects after colistin sulphate administration was
not clear and it was concluded that further research was
necessary.
Either a suboptimal particle size distribution of the
dry powder or the chemical properties of colistin sul-
phate were held responsible for these effects. Improve-
ment of particle size distribution is within reach.
However, if the side effects were provoked by the
physical chemical properties of colistin sulphate, colistin
sulphomethate would be the appropriate chemical form
for further development of a dry powder inhalation
system. To investigate the latter hypothesis while exclud-
ing the first, both colistin salts should be tested in a
dissolved form. Therefore, the aim of this study was to
compare the tolerability of colistin sulphate to colistin
sulphomethate per nebulization in Cystic fibrosis
patients.
2. Materials and methods
2.1. Patients
Nine patients (five females) with CF, diagnosed by
clinical history and confirmed by pathological sweat
tests or DNA analysis, volunteered to participate in the
study. Patients were clinically stable over the last 3
months, as determined by pulmonary function tests. All
patients were chronically infected with P. aeruginosa
and therefore on maintenance treatment with nebulized
colistin sulfomethate. Exclusion criteria were exacerba-
tion of pulmonary infection, colistin hypersensitivity,
treatment with an investigational drug within a month
prior to enrollment, pregnancy, potentially pregnant or
nursing women. The study was performed according to
the Helsinki declaration and was approved by the med-
ical ethical review board of the hospital. Patients were
fully informed by the investigator and a written consent
was obtained from every patient.
2.2. Study protocol
Patients were asked to visit the outpatient clinic two
times, with an interval of at least 5 days. Patients were
instructed not to nebulize colistin or any other inhalation
medication on the morning of the day of visit to the
outpatient clinic. On the first visit, the patient nebulized
a solution of either colistin sulphate or colistin sulphom-
ethate and on the second visit vice versa. This was done
in a randomly assigned doubleblind order. Blinding and
randomisation was performed by the hospital pharmacy.
Lung function tests were performed just before and
15 and 30 min after nebulization was completed.
The patients were asked five questions concerning
their daily use of colistin. The questionnaire and differ-
ent scales used for scoring are given in Fig. 1.
2.3. Materials
Colistin sulphomethate (Colistin parenteral , Grunen- ¨
thal GmbH, Aachen, Germany) and colistin sulphate
(Ph. Eur. 1997, Duchefa, Haarlem, The Netherlands)
were supplied by the hospital pharmacy.
An amount of 160 mg colistin sulphomethate or 100
mg colistin sulphate was dissolved in 6 ml 0.9% aqueous
sodium chloride solution by the hospital pharmacy prior
to the test. The solutions contained an equivalent amount
of colistin (67 mgy6 ml). The pH of the colistin
sulphomethate solution was approximately 7.4; the
osmolality 366 mOsmykg. The pH and osmolality of
the colistin sulphate solution were 5 and 306, respec-
tively (pH meter Metrohm 713, Herisau, Switzerland;
osmolality meter Knauer A 0300, Berlin, Germany).
Nebulization of the colistin solutions was done using
a combination of a Porta-Neb compressor and a
Ventstream jet nebulizer (Medic Aid, Romedic, Meers-
sen, The Netherlands). The patients were instructed to
operate the device until the complete dose was released.
In case of adverse effects of any kind during nebuliza-
tion, participants were allowed to stop the inhalation of
the aerosol temporarily.
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2.4. Pulmonary function
Forced expiratory volume in one second (FEV1) and
forced vital capacity (FVC) were measured using a
calibrated Masterlab pneumotachograph (Jaeger, Wurz-¨
burg, Germany). Lung function tests were performed
following the guidelines of the European Respiratory
Society w4x. A fall in FEV1 of 10% or more was
considered as clinically significant. Percentage changes
are relative to baseline, and not a percentage fall of
predicted.
2.5. Statistical analysis
To compare the effects on lung function of the two
colistin forms, the changes from baseline in the para-
meters FEV1 and FVC, found after administration of
colistin sulphate, were compared to the changes found
after administration of colistin sulphomethate using the
paired Student’s t-test. A P-0.05 was considered to be
significant.
3. Results
Nine patients participated in the study (five females).
Mean age was 29 years (range 20–41). Mean baseline
values (SD) of FEV1 and FVC were 57.8% (11.9%)
and 80.2% (9.5%), respectively (% predicted). After
seven patients had been tested the severity of the adverse
effects caused us to perform an interim analysis. How-
ever, the subsequent two patients were again studied
under blinded conditions.
The pulmonary function test results of the patients
before and after nebulization of either one of the colistin
solutions are presented in Fig. 2.
3.1. Colistin sulphate
Two patients completed nebulization without subjec-
tive adverse effects, despite a decrease in FEV1 of15-0
31.3% and 10.0%, respectively. The remaining seven
patients were not able to complete nebulization of
colistin sulphate because of throat irritation and severe
cough. In one of these seven patients a clinically
significant fall in FEV1 of 31.5% was seen 15 min after
nebulization. Five patients showed a fall in FEV1 15
and 30 min after nebulization and in one patient no
effect on FEV1 was observed. FEV1 values 30 min
after nebulization were not significantly altered com-
pared to ts15 min. Chest tightness was noticed by
those patients who were able to continue nebulization
for a longer period of time. Next to the two patients
that completed nebulization, two patients were able to
nebulize at least 80% of the colistin sulphate solution.
The chest tightness reported by these four patients lasted
2–3 days.
In the seven patients that partially nebulized the
solution, severe coughing was accompanied by perspi-
ration and a sensation of heat. The irritating effect of
the solution was most pronounced in the throat. Some
patients noticed an increased mucus production. All
patients noted an unpleasant taste. One patient needed
treatment with a bronchodilator drug after lung function
tests were completed.
3.2. Colistin sulphomethate
All patients completed nebulization of colistin sul-
phomethate. A clinically significant fall in FEV1 15
min after nebulization was observed in two patients.
This effect ameliorated after 30 min. In one of these
two patients, the fall in FEV1 was accompanied by a
decrease in FVC. This patient indicated that she also
experienced chest tightness during daily colistin nebuli-
zation. No effects other than in daily use were noticed
by the patients.
3.3. Comparison of colistin sulphate to colistin
sulphomethate
The results in Table 1 and Fig. 2 show that the
decrease in lung function is more severe after adminis-
tration of the colistin sulphate than after administration
of colistin sulphomethate. A statistically significant dif-
ference in mean changes in FEV1 , FVC and30-0 15-0
FVC after colistin sulphate nebulization compared to30-0
colistin sulphomethate was observed. However, the dif-
ference in decrease in FEV1 between the two colistin
salts, observed 15 min after nebulization, was not
statistically significant.
3.4. Questionnaire
The questionnaire was intended to give insight in the
daily use of colistin (as sulphomethate) by the patients.
Four patients experienced adverse effects during or after
nebulization (score 3), three patients scored 2 and two
patients did not experience adverse effects at all (score
1). Adverse effects occurred at 0–10 min after starting
nebulization in eight patients and after 10–20 min in
one patient. None of the patients indicated that the
adverse effects influenced their daily life. All patients
used inhalation medication daily. Six patients sometimes
used a short acting b2-sympathicomimetic inhalation
drug.
4. Discussion
The aim of this study was to assess the tolerability,
defined as a possible clinically relevant difference in
pulmonary function and adverse effects, during and after
nebulization of two different chemical entities of colis-
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Fig. 2. Individual FEV1 and FVC-values (deviation from baseline in percentage), for nine patients, after nebulization of colistin sulphate and
colistin sulphomethate respectively.
tin. The results of this study show that nebulization of
colistin sulphate is not tolerated by CF-patients in
contrast to nebulization of colistin sulphomethate.
A relationship between adverse effects and compli-
ance with treatment by CF-patients has been established;
bronchoconstriction may be a reason for poor compli-
ance and discontinuing the therapy w6,7x. Therefore,
colistin sulphate should not be considered as the chem-
ical entity of choice in treatment of CF patients chroni-
cally infected with P. aeruginosa.
The patients in this study were used to daily nebuli-
zation of colistin sulphomethate. Although some
decrease in lung function was observed in all patients
and in two patients a clinically significant decrease in
FEV1 was observed 15 min after nebulization, only one
patient noticed bronchoconstriction.
In contrast, serious side effects (cough and irritation)
and deterioration of lung function were observed after
administration of colistin sulphate. In three patients, a
reduction in FEV1 of 10% or more was observed.
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Table 1
Differences in effect on lung function between colistin sulphate and colistin sulphomethate: mean changes in FEV1 and FVC from baseline values
after administration of colistin sulphate and after colistin sulphomethate have been compared at ts15 and ts30 min
Change in FEV1 (S.D.) Change in FEV1 (S.D.) Change in FVC (S.D.) Change in FVC (S.D.)
(15 min vs. baseline) (30 min vs. baseline) (15 min vs. baseline) (30 min vs. baseline)
Colistin sulphate y11.3% (12.6%) y10.2% (9.4%) y10.4% (9.9%) y10.5% (9.5%)
Colistin sulphomethate y6.0% (7.0%) y2.9% (3.3%) y4.7% (8.1%) y2.1% (4.9%)
Results (difference) y5.3% (12.2%) y7.3% (8.6%) y5.7% (7.3%) y8.4% (7.5%)
Ps0.225 Ps0.034 Ps0.047 Ps0.010
Change in DFEV1 (S.D.): mean change in FEV1 from baseline after colistin sulphate nebulization minus mean change in FEV1 from baseline
after colistin sulphomethate nebulization. SDsstandard deviation.
Change in DFVC (S.D.): mean change in FVC from baseline after colistin sulphate nebulization minus mean change in FVC from baseline
after colistin sulphomethate nebulization. SDsstandard deviation.
The adverse effects found after administration of the
nebulized colistin sulphate solution appeared to be more
serious compared to the adverse effects after dry powder
inhalation, observed by Le Brun et al. w3x.
Bronchoconstriction after inhalation of antibiotics in
CF patients is quite common. Chest tightness after
nebulization of colistin sulphomethate has been reported
in literature w5,6x. Cunningham et al. reported a decrease
in FEV1 of more than 10% in 20 out of 58 children
(34%) immediately and 15 min after nebulization. In
9% of these children, this decrease still persisted at 30
min after nebulization. Maximal bronchoconstriction
was measured immediately after nebulization in 13
patients, after 15 min in five patients and after 30 min
in two patients.
Thirty-five of 46 patients (76%) in a study by
Maddison et al. developed bronchoconstriction after
nebulization of colistin. No definition of clinically sig-
nificant bronchoconstriction was reported by the authors.
Maximal bronchoconstriction was observed immediately
after nebulization in 30 patients, after 15 min in three
patients and after 30 min in two patients. No change in
FEV1 was reported in seven patients.
Recent published data concerning bronchial reactions
to the inhalation of several tobramycin preparations,
including high-dose tobramycin, in 12 CF-patients with
moderate disease show a significant bronchial obstruc-
tion ()10% decrease in mean FEV1) shortly after
nebulization. Bronchoconstriction was most severe after
nebulization of high-dose tobramycin. After 10 min of
inhalation lung function tests had normalised. These
results support the suggestion that lung function tests
generally normalise within 10 min after nebulization
w8x.
Our results show a decrease in FEV1 similar as
described by Cunningham et al. and Maddison et al.
w5,6x. A statistically significant change in mean FEV1,
30 min after nebulization compared to baseline, between
colistin sulphate and colistin sulphomethate was
observed. However, no significant difference in FEV1
at ts15 min between the two colistin salts was seen.
These observations show the lasting effect of colistin
sulphate compared to the relatively rapid recovery of
lung function after colistin sulphomethate nebulization.
If the results of Cunningham et al. and Maddison et
al. would be applicable to our patient group, maximal
bronchoconstriction could have occurred immediately
after cessation of nebulization. Additionally, the decrease
in forced vital capacity at 15 and 30 min compared to
baseline, seen after colistin sulphate nebulization, was
significantly lower compared to nebulized colistin
sulphomethate.
To our knowledge no earlier data concerning the
effect of nebulized colistin sulphate in CF-patients have
been published. The observed effects during and after
colistin sulphate nebulization are caused by a yet
unknown mechanism. Whether the tonicity or pH of
both solutions were of any influence on the results,
remains unclear.
Although adverse effects, related to nebulization of
colistin sulfomethate, were reported in the questionnaire,
none of the patients indicated that it influences their
daily life. Apparently, lung function parameters improve
within 30 min after completing nebulization in most
patients, as proven by our data.
5. Conclusion
This study showed that bronchoconstriction after neb-
ulization of colistin sulphate was significantly more
severe than after nebulization of colistin sulphomethate.
Most patients were forced to stop nebulizing colistin
sulphate because of throat irritation and (severe) cough.
The mechanism causing the observed effects is not
elucidated. As most patients experienced serious side
effects, it is concluded that nebulized colistin as sulphate
is not suitable for treatment of CF patients chronically
infected with P. aeruginosa. Future research towards the
development of a colistin dry powder inhalation will
focus on the use of colistin sulphomethate.
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